Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy

Keloids are common, benign cutaneous overgrowths that manifest clinically as raised, hypertrophic, often hyperpigmented lesions which are formed in response to dermal injury or idiopathic stimuli. Although keloids are a common disease, it's exact incidence and prevalence is not known. Despite the debilitating nature of keloids, current treatment modalities are limited in efficacy; there is no universally effective therapy available to patients. The research team hypothesize that ritlecitinib as a JAK3/TEC inhibitor will be able to reverse both the systemic and local keloid disease process by re-establishing immune homeostasis.

NCT Number	NCT06373458
Lead Sponsor	Icahn School of Medicine at Mount Sinai Collaborators: Pfizer
Conditions	Keloid
Enrollment	30 participants
Start Date	2024-08-13
Primary Completion	2027-08 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2025-09-30